Vanderbilt Center for Neuroscience Drug Discovery Archive — Page 3 of 3

brain illustration
January 14, 2013

AstraZeneca, VU collaborate to develop new treatments for major brain disorders

AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.

By Bill Snyder
Scientific illustration of a magenta G protein-coupled receptor embedded in a gray cell membrane, attached to blue, green, and gold G-protein subunits. Green and red molecular models with arrows indicate exchange of GTP for GDP.
October 18, 2012

Nobel in Chemistry reveals VU ties that bind

Several Vanderbilt researchers have collaborated with this year’s Nobel Chemistry winners.

By Bill Snyder
Assorted brightly colored capsules scattered on a white background.
July 17, 2012

Insights for neuroscience drug discovery

When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects.

By Leigh MacMillan
Laboratory pipette dispensing an amber liquid into a clear multiwell test plate, with a blurred chemical structure in the background.
September 30, 2011

Drug-like molecules aimed at improving treatment of Parkinson’s

Drug-like molecules described by Vanderbilt researchers could lead to Parkinson’s treatments with fewer side effects.

By Bill Snyder